202 related articles for article (PubMed ID: 36162852)
1. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
Yang X; Eriksson M; Czene K; Lee A; Leslie G; Lush M; Wang J; Dennis J; Dorling L; Carvalho S; Mavaddat N; Simard J; Schmidt MK; Easton DF; Hall P; Antoniou AC
J Med Genet; 2022 Dec; 59(12):1196-1205. PubMed ID: 36162852
[TBL] [Abstract][Full Text] [Related]
2. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
Pal Choudhury P; Brook MN; Hurson AN; Lee A; Mulder CV; Coulson P; Schoemaker MJ; Jones ME; Swerdlow AJ; Chatterjee N; Antoniou AC; Garcia-Closas M
Breast Cancer Res; 2021 Feb; 23(1):22. PubMed ID: 33588869
[TBL] [Abstract][Full Text] [Related]
3. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on
Lee A; Mavaddat N; Cunningham A; Carver T; Ficorella L; Archer S; Walter FM; Tischkowitz M; Roberts J; Usher-Smith J; Simard J; Schmidt MK; Devilee P; Zadnik V; Jürgens H; Mouret-Fourme E; De Pauw A; Rookus M; Mooij TM; Pharoah PP; Easton DF; Antoniou AC
J Med Genet; 2022 Dec; 59(12):1206-1218. PubMed ID: 36162851
[TBL] [Abstract][Full Text] [Related]
4. 10-year performance of four models of breast cancer risk: a validation study.
Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
[TBL] [Abstract][Full Text] [Related]
5. Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.
Møller NB; Boonen DS; Feldner ES; Hao Q; Larsen M; Lænkholm AV; Borg Å; Kvist A; Törngren T; Jensen UB; Boonen SE; Thomassen M; Terkelsen T
Sci Rep; 2023 May; 13(1):8536. PubMed ID: 37237042
[TBL] [Abstract][Full Text] [Related]
6. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.
Lee A; Mavaddat N; Wilcox AN; Cunningham AP; Carver T; Hartley S; Babb de Villiers C; Izquierdo A; Simard J; Schmidt MK; Walter FM; Chatterjee N; Garcia-Closas M; Tischkowitz M; Pharoah P; Easton DF; Antoniou AC
Genet Med; 2019 Aug; 21(8):1708-1718. PubMed ID: 30643217
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
[TBL] [Abstract][Full Text] [Related]
8. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.
MacInnis RJ; Bickerstaffe A; Apicella C; Dite GS; Dowty JG; Aujard K; Phillips KA; Weideman P; Lee A; Terry MB; Giles GG; Southey MC; Antoniou AC; Hopper JL
Br J Cancer; 2013 Sep; 109(5):1296-301. PubMed ID: 23942072
[TBL] [Abstract][Full Text] [Related]
9. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
11. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort.
Lakeman IMM; Rodríguez-Girondo M; Lee A; Ruiter R; Stricker BH; Wijnant SRA; Kavousi M; Antoniou AC; Schmidt MK; Uitterlinden AG; van Rooij J; Devilee P
Genet Med; 2020 Nov; 22(11):1803-1811. PubMed ID: 32624571
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.
Ståhlbom AK; Johansson H; Liljegren A; von Wachenfeldt A; Arver B
Fam Cancer; 2012 Mar; 11(1):33-40. PubMed ID: 22124624
[TBL] [Abstract][Full Text] [Related]
13. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
Terkelsen T; Christensen LL; Fenton DC; Jensen UB; Sunde L; Thomassen M; Skytte AB
Fam Cancer; 2019 Oct; 18(4):381-388. PubMed ID: 31435815
[TBL] [Abstract][Full Text] [Related]
14. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
Antoniou AC; Cunningham AP; Peto J; Evans DG; Lalloo F; Narod SA; Risch HA; Eyfjord JE; Hopper JL; Southey MC; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tryggvadottir L; Syrjakoski K; Kallioniemi OP; Eerola H; Nevanlinna H; Pharoah PD; Easton DF
Br J Cancer; 2008 Apr; 98(8):1457-66. PubMed ID: 18349832
[TBL] [Abstract][Full Text] [Related]
15. The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
Antoniou AC; Pharoah PP; Smith P; Easton DF
Br J Cancer; 2004 Oct; 91(8):1580-90. PubMed ID: 15381934
[TBL] [Abstract][Full Text] [Related]
16. Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks.
Wolfson M; Gribble S; Pashayan N; Easton DF; Antoniou AC; Lee A; van Katwyk S; Simard J
Genet Med; 2021 Nov; 23(11):2114-2121. PubMed ID: 34230637
[TBL] [Abstract][Full Text] [Related]
17. The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.
Evans DG; Brentnall A; Byers H; Harkness E; Stavrinos P; Howell A; ; Newman WG; Cuzick J
J Med Genet; 2017 Feb; 54(2):111-113. PubMed ID: 27794048
[TBL] [Abstract][Full Text] [Related]
18. Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases.
Lakeman IMM; Rodríguez-Girondo MDM; Lee A; Celosse N; Braspenning ME; van Engelen K; van de Beek I; van der Hout AH; Gómez García EB; Mensenkamp AR; Ausems MGEM; Hooning MJ; Adank MA; Hollestelle A; Schmidt MK; van Asperen CJ; Devilee P
J Med Genet; 2023 Apr; 60(4):327-336. PubMed ID: 36137616
[TBL] [Abstract][Full Text] [Related]
19. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Antoniou AC; Hardy R; Walker L; Evans DG; Shenton A; Eeles R; Shanley S; Pichert G; Izatt L; Rose S; Douglas F; Eccles D; Morrison PJ; Scott J; Zimmern RL; Easton DF; Pharoah PD
J Med Genet; 2008 Jul; 45(7):425-31. PubMed ID: 18413374
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; McGuffog L; Barrowdale D; Lee A; Soucy P; Dennis J; Domchek SM; Robson M; Spurdle AB; Ramus SJ; Mavaddat N; Terry MB; Neuhausen SL; Schmutzler RK; Simard J; Pharoah PDP; Offit K; Couch FJ; Chenevix-Trench G; Easton DF; Antoniou AC
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
